SEPTInvestingStart Free

FULC 8-K: Divestiture

Fulcrum Therapeutics

Filed with the SEC on · accession 0001193125-26-458387

FULC filed a 8-K (current report) with the SEC on Nov 12, 2026. Fulcrum Therapeutics entered into an asset purchase agreement with Slate Medicines to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third-party pharmaceutical company for approximately $7.0 million in cash. The stock moved -1.6% by the first close after the filing.

Summary of the filing

Fulcrum Therapeutics entered into an asset purchase agreement with Slate Medicines to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third-party pharmaceutical company for approximately $7.0 million in cash. The closing is contingent on the consummation of the proposed merger between Fulcrum and Slate, and proceeds are expected to be funded into escrow and credited to Fulcrum's net cash, increasing the cash dividend expected in connection with the merger.

For details, click here →How to read a 8-K →

Key details

Cash proceeds from sale of early-stage HbF assets$7.0M
SellerFulcrum Therapeutics, Inc.
Counterparty to asset purchase agreement and merger partnerSlate Medicines, Inc.
Buyer of early-stage hbf assetsUnaffiliated third-party pharmaceutical company

How FULC stock reacted

Close before

$3.74

Nov 11, 2026

First close after

-1.60%

$3.68

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for FULC, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for FULC?

Click here

Frequently asked questions

What did FULC file with the SEC on Nov 12, 2026?

FULC filed a 8-K (Divestiture). Fulcrum Therapeutics entered into an asset purchase agreement with Slate Medicines to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third-party pharmaceutical company for approximately $7.0 million in cash. The closing is contingent on the consummation of the proposed merger between Fulcrum and Slate, and proceeds are expected to be funded into escrow and credited to Fulcrum's net cash, increasing the cash dividend expected in connection with the merger.

What does a divestiture mean for FULC stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did FULC stock react to this filing?

FULC closed at $3.74 before the filing and $3.68 on Nov 12, 2026 (-1.60%).

Other FULC SEC filings

Get alerts when FULC files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
FULC overviewFULC analysisFULC newsLatest SEC filings